Focus on ziprasidone: A review of its use in child and adolescent psychiatry

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Volumn 17, Issue 4, 2008, Pages 220-229

  Elbe, Dean ^a   Carandang, Carlo G ^b,c  

^a BC CHILDREN S HOSPITAL   (Canada)

^b IWK HEALTH CENTRE   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Adolescent; Child; Psychopharmacology; Review; Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; ZIPRASIDONE;

ABDOMINAL PAIN; AGITATION; AKATHISIA; AUTISM; BIPOLAR DISORDER; BLURRED VISION; CHILD PSYCHIATRY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOOD; FOOD DRUG INTERACTION; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART PALPITATION; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; INSULIN BLOOD LEVEL; LETHARGY; LOW DRUG DOSE; MANIA; MENTAL DISEASE; METABOLIC DISORDER; MORNING DOSAGE; MUSCLE STIFFNESS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NOSE CONGESTION; OCULOGYRIC CRISIS; ORTHOSTATIC HYPOTENSION; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH DISCOMFORT; SUICIDAL IDEATION; TACHYCARDIA; TIC; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 63449108645     PISSN: 17198429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Alessi, N. E. (2003). Ziprasidone in autism. Journal of the American Academy of Child and Adolescent Psychiatry, 42(6), 622-623.
2. Antia, S. X., Sholevar, E. H. & Baron, D. A. (2005). Overdoses and ingestions of second-generation antipsychotics in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 15(6), 970-985. doi:10.1089/cap.2005.15.970.
3. Barnett, M. S. (2004a). Ziprasidone and mania. Journal of the American Academy of Child and Adolescent Psychiatry, 43(4), 380.
4. Barnett, M. S. (2004b). Ziprasidone monotherapy in pediatric bipolar disorder. Journal of Child and Adolescent Psychopharmacology, 14(3), 471-477. doi:10.1089/cap.2004.14.471.
5. Barrett, E., Blonde, L., Clement, S., Davis, J., Devlin, J., Kane, J. et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596-601.
6. Barzman, D. H., DelBello, M. P., Forrester, J. J., Keck, P. E., Jr. & Strakowski, S. M. (2007). A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: Prospective studies are needed. Journal of Child and Adolescent Psychopharmacology, 17(4), 503-509. doi:10.1089/ cap.2007.0124.
7. Biederman, J., Mick, E., Spencer, T., Dougherty, M., Aleardi, M. & Wozniak, J. (2007). A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Bipolar Disorders, 9(8), 888-894. doi:10.1111/ j.1399-5618.2007.00450.x.
8. Blair, J., Scahill, L., State, M. & Martin, A. (2005). Electrocardiographic changes in children and adolescents treated with ziprasidone: A prospective study. Journal of the American Academy of Child and Adolescent Psychiatry, 44(1), 73-79.
9. Centre for Evidence Based Medicine. (2001). Levels of evidence. Retrieved July 16, 2008, from http://www.cebm.net/index.aspx?o=1025.
10. Delbello, M. P., Findling, R. L., Wang, P. P., Gundapaneni, B. & Versavel, M. (2008). Efficacy and Safety of Ziprasidone in Pediatric Bipolar Disorder. Poster presented at the Annual Meeting of the American Psychiatric Association, Washington, DC.
11. Findling, R. L., Delbello, M. P., Wang, P. P., Bachinsky, M., Gundapaneni, B. & Versavel, M. (2008). Long-term safety and tolerability of ziprasidone in children and adolescents with bipolar disorder. Poster presented at the Annual Meeting of the American Psychiatric Association, Washington, DC.
12. Goforth, H. W. & Rao, M. S. (2003). Improvement in behaviour and attention in an autistic patient treated with ziprasidone. The Australian and New Zealand Journal of Psychiatry, 37(6), 775-776.
13. Haddad, P. M., Anderson, I. M. (2002). Antipsychotic- Related QTc Prolongation, Torsade de Pointes and Sudden Death. Drugs, 62(11), 1649-1671.
14. Hazaray, E., Ehret, J., Posey, D. J., Petti, T. A. & McDougle, C. J. (2004). Intramuscular ziprasidone for acute agitation in adolescents. Journal of Child and Adolescent Psychopharmacology, 14(3), 464-470. doi:10.1089/cap.2004.14.464
15. Health Canada. Summary Basis of Decision (SBD) - Zeldox® (ziprasidone hydrochloride monohydrate). Ottawa, ON: Health Products and Food Branch, 2008. [cited 2008 Jul 31]. Available from http://205.193.93.51/NocWeb/viewnoce.jsp?noc=jrpf.
16. International Journal of Pharmaceutical Compounding (2008). Formulations Related Articles. [cited 2008 Aug 7]. Available from http://www.ijpc.com/editorial/SearchByTopic.cfm?CatID=9.
17. Jaworowski, S., Hauser, S., Mergui, J. & Hirsch, H. (2004). Ziprasidone and weight gain. Clinical Neuropharmacology, 27(2), 99-100.
18. Jordan, M. P. (2003). Ziprasidone-associated galactorrhea in a female teenager. Journal of the American Academy of Child and Adolescent Psychiatry, 42(1), 4-5.
19. Khan, S. S. & Mican, L. M. (2006). A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 16(6), 671-677. doi:10.1089/cap.2006.16.671.
20. Kutcher, S., Brooks, S. J., Gardner, D. M., Honer, B., Kopala, L., Labelle, A. et al (2005). Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders. Neuropsychiatric Disease and Treatment. 1 (2), 89-108.
21. Larson, M. F. & Hauser, A. (2003). Possible ziprasidone-induced mania. Journal of the American Academy of Child and Adolescent Psychiatry, 42(9), 1012; discussion 1012-3.
22. Leibold, J., Patel, V. & Hasan, R. A. (2004). Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clinical Therapeutics, 26(7), 1105-1108.
23. Malone, R. P., Delaney, M. A., Hyman, S. B. & Cater, J. R. (2007). Ziprasidone in adolescents with autism: An open-label pilot study. Journal of Child and Adolescent Psychopharmacology, 17(6), 779-790. doi:10.1089/cap.2006.0126.
24. McDougle, C. J., Kem, D. L. & Posey, D. J. (2002). Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 41(8), 921-927.
25. Meighen, K. G., Shelton, H. M. & McDougle, C. J. (2004). Ziprasidone treatment of two adolescents with psychosis. Journal of Child and Adolescent Psychopharmacology, 14(1), 137-142. doi:10.1089/ 104454604773840580.
26. Pfizer. (2007). Geodon® prescribing information. Retrieved July 14, 2008, from http://www.pfizer.com/pfizer/download/ uspi_geodon.pdf.
27. Pfizer Canada Inc. (2007). Zeldox® product monograph. Kirkland, QC: Pfizer Canada Inc. 2007. [cited 2008 Aug 7] Available from http://www.pfizer.ca/ourproducts/prescriptionpharmaceuticals/ default.asp?s=1&id=42&doc=enmonograph.
28. Pfizer Canada Inc. (2008). New schizophrenia treatment now available in Canada. Retrieved July 8, 2008, from http://www.pfizer.ca/ english/newsroom/press%20releases/default.asp?s=1&releaseID=258.
29. Piotrovsky V. Pharmacokinetic-Pharmacodynamic Modeling in the Data Analysis and Interpretation of Drug-induced QT/QTc Prolongation. AAPS Journal. 2005; 7(3): E609-E624. doi: 10.1208/aapsj070363.
30. Ramos, A. E., Shytle, R. D., Silver, A. A. & Sanberg, P. R. (2003). Ziprasidone-induced oculogyric crisis. Journal of the American Academy of Child and Adolescent Psychiatry, 42(9), 1013-1014.
31. Saldana, S. N. & Delgado, S. V. (2007). Ziprasidone-associated galactorrhea in an adolescent female. Journal of Child and Adolescent Psychopharmacology, 17(2), 259-260. doi:10.1089/cap.2006.0053.
32. Sallee, F. R., Gilbert, D. L., Vinks, A. A., Miceli, J. J., Robarge, L. & Wilner, K. (2003). Pharmacodynamics of ziprasidone in children and adolescents: Impact on dopamine transmission. Journal of the American Academy of Child and Adolescent Psychiatry, 42(8), 902-907. doi:10.1097/01.CHI.0000046897.27264.46.
33. Sallee, F. R., Kurlan, R., Goetz, C. G., Singer, H., Scahill, L., Law, G., et al. (2000). Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 39(3), 292-299.
34. Sallee, F. R., Miceli, J. J., Tensfeldt, T., Robarge, L., Wilner, K. & Patel, N. C. (2006). Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 45(6), 720-728. doi:10.1097/01.chi.0000215347.93902.3e.
35. Seeger, T. F., Seymour, P. A., Schmidt, A. W., Zorn, S. H., Schulz, D. W., Lebel, L. A., et al. (1995). Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. The Journal of Pharmacology and Experimental Therapeutics, 275(1), 101-113.
36. Staller, J. A. (2004). Intramuscular ziprasidone in youth: A retrospective chart review. Journal of Child and Adolescent Psychopharmacology, 14(4), 590-592. doi:10.1089/cap.2004.14.590.
37. Stigler, K. A., Potenza, M. N., Posey, D. J. & McDougle, C. J. (2004). Weight gain associated with atypical antipsychotic use in children and adolescents: Prevalence, clinical relevance, and management. Paediatric Drugs, 6(1), 33-44.
38. Versavel, M., Delbello, M. P., Ice, K., Kowatch, R., Keller, D. & Miceli, J. (2005). Ziprasidone Dosing Study in Pediatric Patients with Bipolar Disorder, Schizophrenia, or Schizoaffective Disorder. Neuropsychopharmacology, 30 (suppl 1): S122-3. [abstract].
39. Yumru, M., Savas, H. A., Selek, S. & Savas, E. (2006). Acute dystonia after initial doses of ziprasidone: A case report. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 30(4), 745-747. doi:10.1016/j.pnpbp.2006.01.024.